TY  - GEN
AU  - Yu,Ming-Lung
AU  - Chen,Yao-Li
AU  - Huang,Chung-Feng
AU  - Lin,Kuo-Hua
AU  - Yeh,Ming-Lun
AU  - Huang,Ching-I
AU  - Hsieh,Meng-Hsuan
AU  - Lin,Zu-Yau
AU  - Chen,Shinn-Cherng
AU  - Huang,Jee-Fu
AU  - Dai,Chia-Yen
AU  - Chuang,Wan-Long
TI  - Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience
SN  - 0929-6646
PY  - 2018///1016
KW  - 2-Naphthylamine
KW  - Aged
KW  - Alanine Transaminase
KW  - blood
KW  - Anilides
KW  - adverse effects
KW  - Antiviral Agents
KW  - Carbamates
KW  - Cyclopropanes
KW  - Drug Therapy, Combination
KW  - Female
KW  - Hepacivirus
KW  - genetics
KW  - Hepatitis C, Chronic
KW  - complications
KW  - Humans
KW  - Lactams, Macrocyclic
KW  - Liver Cirrhosis
KW  - physiopathology
KW  - Liver Transplantation
KW  - Macrocyclic Compounds
KW  - Male
KW  - Middle Aged
KW  - Postoperative Period
KW  - Proline
KW  - analogs & derivatives
KW  - Ribavirin
KW  - Ritonavir
KW  - Sulfonamides
KW  - Sustained Virologic Response
KW  - Uracil
KW  - Valine
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1016/j.jfma.2017.06.006
ER  -